CDT
CDT Equity Inc.
$2.01
-3.61%
2026-05-08
About CDT Equity Inc.
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Key Fundamentals
EPS (TTM)
$-1177.89
Profit Margin
0.0%
Debt/Equity
43.83
Price/Book
0.20
Beta
1.57
Market Cap
$10.4M
Avg Volume (10D)
34K
Recent Breakout Signals
No recent breakout signals detected for CDT.
Recent Price Range (60 Days)
60D High
$11.00
60D Low
$0.37
Avg Volume
330K
Latest Close
$2.01
Get breakout alerts for CDT
Sign up for Breakout Scanner to receive daily notifications when CDT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
CDT Equity Inc. (CDT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CDT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CDT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.